Evidence map›Paper›PMID 36225275›Full record

ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2022

May Measurement Month 2017-2019: results from Switzerland

Aikaterini Damianaki, Wei Wang, Thomas Beaney, Thilo Burkard, Isabella Sudano, Michel Burnier, Gregoire Wuerzner

Abstract read
In one paragraph

Article in European heart journal supplements : journal of the European Society of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aikaterini DamianakiService of Nephrology and hypertension, Lausanne University Hospital and University of Lausanne, Rue de Bugnon 17, 1005 Lausanne, Switzerland.
Wei WangImperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London, W12 7RH, UK.
Thomas BeaneyImperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London, W12 7RH, UK.
Thilo BurkardMedical Outpatient Department and Hypertension Clinic, University Hospital Basel, Basel, Switzerland.
Isabella SudanoDepartment of Cardiology, University Heart Center Zürich, Zürich, Switzerland.
Michel BurnierService of Nephrology and hypertension, Lausanne University Hospital and University of Lausanne, Rue de Bugnon 17, 1005 Lausanne, Switzerland.
Gregoire WuerznerService of Nephrology and hypertension, Lausanne University Hospital and University of Lausanne, Rue de Bugnon 17, 1005 Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-6424-7630

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

May Measurement Month (MMM) is an international screening campaign for arterial hypertension initiated by the International Society of Hypertension and endorsed by the World Hypertension League. Its aim is to raise the awareness of elevated blood pressure (BP) in the population worldwide. The goal of the present analyses is to assess the results obtained during three years of this campaign in Switzerland. Swiss data from MMM17 to MMM19 campaigns were used. BP and a questionnaire for basic demographic and clinical information were recorded for each participant. BP measurements and definition of arterial hypertension followed the standard MMM protocol. To assess BP control, European Society of Hypertension 2018 thresholds of <140/90 mmHg were used. Overall, 3635 participants had their BP measured, including 2423 women (66.7%) and 1212 (33.3%) men. More than half of the data came from pharmacies during MMM18 and MMM 19 campaigns. The difference in BP between pharmacies and other screenings sites was small. Overall, prevalence and awareness rates were 32.7% and 72.3%, respectively. Of those on medication, 60.9% were controlled, and of all hypertensive patients, 39.4% had controlled BP. In Switzerland, the prevalence of hypertension based on a 3-year awareness campaign was similar to previous epidemiological data within the country. One third of the population screened had hypertension, two thirds were aware of it, and less than half had controlled BP.

Indexed as

Blood pressureHypertensionMMMPrevalenceScreeningSwitzerland

Identifiers

PMID36225275
PMCPMC9547513

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.